WASHINGTON (AP) — Federal regulators are challenging patents on 20 brand name drugs, including the blockbuster weight-loss injection Ozempic, in the latest action by the Biden administration targeting industry practices that drive up pharmaceutical prices.
The Federal Trade Commission on Tuesday sent warning letters to 10 drugmakers, taking issue with patents on popular drugs for weight loss, diabetes, asthma and other reparatory conditions. The letters allege that certain patents filed by Novo Nordisk, GlaxoSmithKline, AstraZeneca and seven other companies are inaccurate or misleading.
Brand-name drugmakers use patents to protect their medicines and stave off cheaper, generic medicines. Most blockbuster drugs are protected by dozens of patents covering various ingredients, manufacturing processes and intellectual property. Generic drugmakers can only launch their own cheaper versions if the patents have expired or are successfully challenged in court.
Related articles:
Related suggestion:
Changsha captures hearts of HK touristsQiaopi, Letters of Love from Overseas ChineseQiaopi, Letters of Love from Overseas ChineseRoundup: Overseas Experts Hail Xi's Notion of Building Modern Chinese CivilizationReading This Book to Understand China in the New EraGLOBALinkWorld Insights: How China Strives to Improve Global Human Rights Governance for a Better WorldYangtze town has a foot in the past and an eye on the futureGuizhou mountain tourism is peak treatXi Sends Congratulatory Letter to 15th Straits Forum
2.1623s , 6498.8984375 kb
Copyright © 2024 Powered by US challenges 'bogus' patents on Ozempic and other drugs in effort to spur competition ,Worldly Wonders news portal